<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01357421</url>
  </required_header>
  <id_info>
    <org_study_id>NMX-103</org_study_id>
    <nct_id>NCT01357421</nct_id>
  </id_info>
  <brief_title>Effects of TT301 on Cytokine Levels Post Endotoxin Challenge</brief_title>
  <official_title>A Phase 1 Double-blind, Randomized, Placebo-controlled Study Evaluating the Effects of a Single Intravenous Dose of TT301 on LPS-induced Changes in Blood Cytokine Levels in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OPKO Health, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OPKO Health, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effects of TT301 on cytokine levels in healthy male volunteers&#xD;
      participating in an endotoxin challenge.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The LPS human endotoxemia model results in a well characterized, transient acute inflammatory&#xD;
      response. The model has been widely used for decades as a system to study new therapeutic&#xD;
      agents for inflammation before wider clinical studies are undertaken. This study will&#xD;
      evaluate the effects of TT301 on cytokine levels in healthy male volunteers participating in&#xD;
      an endotoxin challenge.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cytokine levels post LPS challenge</measure>
    <time_frame>Measured up to 12h post-LPS</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>TT301</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational drug TT301</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TT301</intervention_name>
    <description>Single iv dose of TT301</description>
    <arm_group_label>TT301</arm_group_label>
    <other_name>TT301 iv</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single iv dose of 0.9% sodium chloride for injection USP</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>0.9% sodium chloride for injection USP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male&#xD;
&#xD;
          -  18 to 40 years, inclusive&#xD;
&#xD;
          -  55 - 95 kg, inclusive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of any clinically significant disease&#xD;
&#xD;
          -  History of cancer&#xD;
&#xD;
          -  History of syncope or severe vasovagal events&#xD;
&#xD;
          -  Antibiotic treatment within 60 days of Day 1&#xD;
&#xD;
          -  Surgical procedure within 60 days of Day 1&#xD;
&#xD;
          -  Hepatitis C, Hepatitis B&#xD;
&#xD;
          -  Tuberculosis&#xD;
&#xD;
          -  HIV&#xD;
&#xD;
          -  Requirement for medications (prescription/OTC) during the study&#xD;
&#xD;
          -  Donated &gt; 250 mL blood within 30 days of Day 1&#xD;
&#xD;
          -  Donated &gt; 750 mL blood within 60 days of Day 1&#xD;
&#xD;
          -  In a clinical trial of an immunosuppressive drug within 6 months of Day 1&#xD;
&#xD;
          -  Received any vaccination within 6 months of Day 1&#xD;
&#xD;
          -  Any clinically important allergy&#xD;
&#xD;
          -  Known allergy/sensitivity to lactose and/or polyethylene glycol&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Agensky, BSc, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Transition Therapeutics Inc. / Waratah Pharmaceuticals Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Clinical Research Unit</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>May 13, 2011</study_first_submitted>
  <study_first_submitted_qc>May 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2011</study_first_posted>
  <last_update_submitted>June 4, 2013</last_update_submitted>
  <last_update_submitted_qc>June 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

